Table 2.
Selected ongoing trials in adoptive cell transfer (ACT) therapies across different cancer types (clinicaltrials.gov, accessed on 1 March 2024).
| Condition | Intervention | Gov. Identifier | Phase | Status | Enrollment |
|---|---|---|---|---|---|
| CAR-T | |||||
| GD2-expressing brain tumor | GD2 CAR-T | NCT03373097 | I | Recruiting | 34 |
| CLDN6-positive relapsed or refractory advanced solid tumors | CLDN6 CAR-T CLDN6 uRNA-LPX/CLDN6 modRNA-LPX (mRNA vaccine) |
NCT04503278 | I/IIa | Recruiting | 145 |
| Children with recurrent/refractory malignant brain tumors | IL13Ralpha2 targeting Hinge-optimized 41BB-co-stimulatory CD19-CAR-T Fludarabine Cyclophosphamide |
NCT04510051 | I | Recruiting | 18 |
| Multiple myeloma | SLAMF7 CAR-T BCMA CAR-T Bortezomib Dexamethasone Lenalidomide Cyclophosphamide Fludarabine |
NCT04499339 NCT04923893 |
I/IIa III |
Recruiting | 38 650 |
| CD30+ refractory/relapsed Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) | CD30 CAR-T | NCT02690545 | Ib/II | Recruiting | 40 |
| Relapsed or refractory B-cell lymphoma | CD19-CD22 CAR-T | NCT04715217 | I/II | Recruiting | 24 |
| Malignant pleural disease | Mesothelin CAR-T Cyclophosphamide Pembrolizumab |
NCT02414269 | I/II | Active, not recruiting | 113 |
| CD70-expressing cancers | CD70 CAR-T | NCT02830724 | I/II | Recruiting | 124 |
| CAR-NK | |||||
| Stage IV ovarian cancer, refractory testis cancer, recurrent endometrial cancer CAR NK | CLDN6 targeting CAR-NK cells | NCT05410717 | I/IIa | Recruiting | 200 |
| Metastatic locally advanced gastric/GEJ cancer or HNSCC | PD-L1 t-haNK N-803 Pembrolizumab (anti-PD-1) |
NCT04847466 | II | Recruiting | 55 |
| Relapsed/refractory NHL, CLL) or B-cell acute lymphoblastic leukemia (B-ALL) | Allogenic CD19-CAR-NK | NCT05020678 | I | Recruiting | 150 |
| Refractory metastatic colorectal cancer | NKG2D CAR-NK | NCT05213195 | I | Recruiting | 38 |
| CAR-Gamma Delta T cells | |||||
| B-cell malignancy | CD20 Allogenic Gamma Delta CAR-T Fludarabine Cyclophosphamide |
NCT04735471 | I | Recruiting | 78 |
| TCR-T | |||||
| Induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers | Conditioning, E7 TCR-T cells Aldesleukin (IL-2) |
NCT05639972 | I/II | Recruiting | 15 |
| TCR against neoantigens in subjects with relapsed/refractory solid tumors (gynecologic colorectal, pancreatic, NSCLC, ovarian cancer) | Neoantigen-specific TCR-T cell Aldesleukin |
NCT05194735 | I/II | Active, not recruiting | 180 |
| Previously untreated advanced melanoma | PRAM (PReferentially expressed antigen in Melanoma) TCR-T Nivolumab (anti PD-1) Nivolumab + Relatlimab (anti LAG3) |
NCT05122221 | III | Recruiting | 12 |
| Refractory mesothelin-expressing mesothelioma (MPM), ovarian cancer (OvC), cholangiocarcinoma (CHO), or NSCLC | Gavocabtagene autoleucel (Mesothelin targeted TCR-T) Fludarabine Cyclophosphamide Nivolumab Ipilimumab |
NCT03907852 | II | Recruiting | 175 |
| KRAS G12V-expressing solid tumors | KRAS G12V targeted TCR-T | NCT06105021 | I/II | Recruiting | 100 |
| Tumor-Infiltrating Lymphocyte (TIL) therapy | |||||
| Metastatic CRC, ovarian, pancreatic, and breast cancer | Young TIL Pembrolizumab Aldesleukin Chemotherapy |
NCT01174121 | II | Recruiting | 332 |
| Recurrent, metastatic, or persistent cervical carcinoma | Autologous TIL (IL-145) Pembrolizumab IL-2 |
NCT03108495 | II | Recruiting | 189 |